Insider · CIK 0001993953
Michael Lee Milligan
Files at NMRA (Neumora Therapeutics, Inc.). First filing Feb 19, 2026, latest Feb 19, 2026.
In brief
Michael Lee Milligan files SEC Form 4 as officer at NMRA (Neumora Therapeutics, Inc.). Since Feb 19, 2026, Michael Lee Milligan has reported 0 open-market buys worth $0 and 1 open-market sell worth $5,119, the latest filed on Feb 19, 2026.
A track record needs three past buys with six months of prices behind them; Michael Lee Milligan has 0, so none is measured yet.
The newest scored trade: sold $5,119 of NMRA on Feb 17, 2026, filed Feb 19, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $5,119.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NMRA: Neumora Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Neumora Therapeutics, Inc. | $5,119 1,436 shares | -6% | +476% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 17, 2026 | NMRA Neumora Therapeutics, Inc. | 1,436 0.00% of outstanding | $5,119 | Feb 17, 2026 | none |
| Feb 18, 2025 | NMRA Neumora Therapeutics, Inc. | 1,978 0.00% of outstanding | $3,351 | Feb 18, 2025 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Aug 21, 2026 |
| Feb 17, 2026 | NMRA Neumora Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,436 | $3.57 | $5,119 | 21,034 | Feb 19, 2026 |
| Jan 8, 2026 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Jan 9, 2026 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -85,391 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -38,234 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,675 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -41,250 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +85,391 | - | - | 85,391 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +38,234 | - | - | 38,234 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,675 | - | - | 28,675 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +41,250 | - | - | 41,250 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | - | - | 400,000 | May 30, 2025 |
Questions about Michael Lee Milligan
Answered from the filings on this page, as of the latest one.
Is Michael Lee Milligan buying or selling?
In the last 12 months Michael Lee Milligan reported 0 open-market buys worth $0 and 1 open-market sell worth $5,119 on SEC Form 4; the latest was sold $5,119 of NMRA on Feb 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Michael Lee Milligan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Lee Milligan has 0.
Where does Michael Lee Milligan file Form 4?
Michael Lee Milligan has filed Form 4 at NMRA (Neumora Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.